[시장보고서]시각장애 치료제 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 처방 유형별, 치료제별, 최종사용자별, 지역별, 경쟁별(2020-2030년)

시각장애 치료제 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 처방 유형별, 치료제별, 최종사용자별, 지역별, 경쟁별(2020-2030년)

Optical Disorders Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Prescription Type, By Therapeutics, By End User, By Region and Competition, 2020-2030F

상품코드 : 1703296

리서치사 : TechSci Research

발행일 : 2025년 04월

페이지 정보 : 영문 182 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,500

￦ 6,511,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500

￦ 7,957,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000

￦ 11,575,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

시각장애 치료제 세계 시장은 2024년 376억 8,000만 달러로 평가되었고, 2030년에는 603억 5,000만 달러에 달할 것으로 예상되며, 예측 기간 동안 8.14%의 연평균 성장률(CAGR)을 보일 것으로 예측됩니다.

안과 질환 또는 안질환이라고도 불리는 시각장애은 눈과 시각계에 영향을 미치는 광범위한 증상을 포함합니다. 이러한 질환은 안구 구성 요소의 구조와 기능을 손상시켜 시각 장애, 불편함 및 기타 증상을 유발합니다. 이러한 질환은 모든 연령대에 영향을 미칠 수 있으며, 경증부터 중증까지 다양한 증상을 유발할 수 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	376억 8,000만 달러
시장 규모 : 2030년	603억 5,000만 달러
CAGR : 2025-2030년	8.14%
급성장 부문	일반의약품
최대 시장	북미

시력장애의 치료법은 다양하며, 증상의 성격과 진행 정도에 따라 달라집니다. 교정 렌즈(안경이나 콘택트렌즈), 약리 요법(점안제나 먹는 약), 수술, 생활습관 개선, 조기 발견과 지속적인 모니터링을 위한 정기적인 안과 검사 등이 있습니다. 이러한 치료의 종합적인 목표는 시기능을 유지하고 눈의 전반적인 건강을 유지하는 것입니다.

주요 시장 성장 촉진요인

기술 발전

주요 시장 이슈

제네릭 의약품 경쟁사

주요 시장 동향

환자 중심의 치료 접근법

시장 규모와 예측
- 금액별
시장 점유율과 예측
- 처방전 유형별(시판약, 처방 안과약)
- 치료제별(노인황반변성, 결막염, 당뇨병성 황반부종, 당뇨병 망막증, 안구건조증, 안구암, 녹내장 등)
- 최종사용자별(진단센터, 안과 클리닉, 병원)
- 기업별(2024년)
시장 맵

제6장 아시아태평양의 시각장애 치료제 시장 전망

시장 규모와 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
- 중국
- 인도
- 호주
- 일본
- 한국

제7장 유럽의 시각장애 치료제 시장 전망

시장 규모와 예측
시장 점유율과 예측
유럽 : 국가별 분석
- 프랑스
- 독일
- 스페인
- 이탈리아
- 영국

제8장 북미의 시각장애 치료제 시장 전망

시장 규모와 예측
시장 점유율과 예측
북미 : 국가별 분석
- 미국
- 멕시코
- 캐나다

제9장 남미의 시각장애 치료제 시장 전망

시장 규모와 예측
시장 점유율과 예측
남미 : 국가별 분석
- 브라질
- 아르헨티나
- 콜롬비아

제10장 중동 및 아프리카의 시각장애 치료제 시장 전망

시장 규모와 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트(UAE)

제11장 시장 역학

성장 촉진요인
과제

제12장 시장 동향과 발전

최근 동향
제품 출시
인수합병(M&A)

제13장 세계의 시각장애 치료제 시장 : SWOT 분석

제14장 Porter의 Five Forces 분석

업계내 경쟁
신규 참여 가능성
공급업체의 힘
고객의 힘
대체품의 위협

제15장 PESTEL 분석

제16장 경쟁 구도

Alcon Inc.
Novartis ag
Johnson & Johnson services, Inc.
Bausch health
Merck & co. Inc.
Coherus biosciences, Inc.
Allergan
Pfizer, Inc.
Bayer ag
Santen pharmaceuticals co. Ltd.
Genetech, Inc.

제17장 전략적 제안

제18장 리서치사에 대해 & 면책사항

LSH

영문 목차

영문목차

Global Optical Disorders Drugs Market for optical disorders drugs was valued at USD 37.68 billion in 2024 and is projected to reach USD 60.35 billion by 2030, expanding at a compound annual growth rate (CAGR) of 8.14% during the forecast period. Optical disorders, also referred to as ophthalmic or eye disorders, encompass a broad spectrum of conditions affecting the eyes and the visual system. These disorders can impair the structure or function of ocular components, leading to visual disturbances, discomfort, or additional symptoms. They can affect individuals across all age groups and vary in severity from mild to debilitating.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 37.68 Billion
Market Size 2030	USD 60.35 Billion
CAGR 2025-2030	8.14%
Fastest Growing Segment	Over-The-Counter Drugs
Largest Market	North America

Treatment options for optical disorders are diverse and depend on the nature and progression of the condition. Interventions may include corrective lenses (eyeglasses or contact lenses), pharmacological therapies (eye drops or oral medications), surgical procedures, lifestyle changes, and routine eye examinations aimed at early detection and ongoing monitoring. The overarching goal of these treatments is to preserve visual function and maintain overall ocular health.

Key Market Drivers

Technological Advancements

Recent technological progress in ophthalmology has significantly shaped the pharmaceutical landscape. One major development is the introduction of sustained-release drug delivery systems that provide controlled and extended medication release, reducing the frequency of administration. A notable example is Roche's Susvimo (ranibizumab injection), which received FDA approval in February 2025 for the treatment of diabetic macular edema (DME). It is the first and only FDA-approved therapy shown to maintain vision in DME patients with fewer treatments compared to standard care.

Nanotechnology is playing a critical role in enhancing ocular drug delivery. Nanogels and other nano-sized carriers have demonstrated improved tissue penetration and bioavailability, particularly in treating anterior segment conditions such as glaucoma, cataracts, dry eye syndrome, and bacterial keratitis.

Advancements in topical ophthalmic formulations are also contributing to market growth. For example, lipid-based eye drops have been developed to effectively manage evaporative dry eye disease by stabilizing the tear film and reducing tear evaporation.

Biotechnology has facilitated the emergence of gene therapies that target specific molecular pathways involved in various ocular diseases. These therapies have shown potential in delivering long-term visual improvements for patients suffering from inherited or degenerative retinal conditions.

Key Market Challenges

Generic Competition

The growing presence of generic drugs poses a significant challenge for brand-name pharmaceutical companies operating in the optical disorders segment. Once patent protections expire, lower-cost generics enter the market, often at substantially reduced prices, impacting revenue streams of original drug manufacturers. Patients and healthcare providers frequently opt for generics due to their affordability, leading to decreased market share for innovator products.

The rapid adoption of generics can lead to price erosion and force originator companies to reduce prices or offer discounts to maintain competitiveness. This shift adversely affects profit margins and limits the ability to reinvest in research and development (R&D). Moreover, the loss of exclusivity following patent expiry often results in diminished market dominance.

This competitive pressure can discourage pharmaceutical firms from pursuing new drug innovations in the ophthalmic space, given the reduced commercial incentives once generics become viable. As a result, companies must carefully balance R&D investments with strategic planning to mitigate the risks associated with generic competition.

Key Market Trends

Patient-Centric Treatment Approaches

There is a growing trend toward tailoring ophthalmic treatment plans to align with individual patient preferences and lifestyles. Healthcare providers are increasingly considering factors such as daily routines, treatment goals, and comfort when selecting medications and therapeutic approaches.

Patients express varied preferences for modes of drug administration-some favor eye drops, while others may opt for ointments or less frequent dosing schedules. In response, pharmaceutical companies are expanding their product portfolios to include a range of delivery formats designed for ease of use and integration into daily life.

User-friendly packaging and intuitive application mechanisms are being developed to improve adherence to treatment protocols. Additionally, reducing the occurrence of side effects is a major focus in drug development, as improved tolerability leads to higher compliance and better clinical outcomes.

Flexibility in dosing is also highly valued by patients. Drugs offering once-daily or extended dosing intervals provide greater convenience and enhance patient autonomy. The industry is further shifting toward collaborative care models, emphasizing patient education and shared decision-making between patients and healthcare providers. This approach ensures that treatment plans reflect individual values and objectives, leading to increased satisfaction and better management of eye disorders.

Key Market Players

Alcon Inc.
Novartis ag
Johnson & Johnson services, Inc.
Bausch health
Merck & co. Inc.
Coherus biosciences, Inc.
Allergan
Pfizer, Inc.
Bayer ag
Santen pharmaceuticals co. Ltd.
Genetech, Inc.

Report Scope:

In this report, the Global Optical Disorders Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Optical Disorders Drugs Market, By Prescription Type:

Over-The-Counter Drugs
Prescription Ophthalmic Drugs

Optical Disorders Drugs Market, By Therapeutics:

Age-Related Macular Degeneration
Conjunctivitis
Diabetic Macular Edema
Diabetic Retinopathy
Dry Eye
Eye Cancer
Glaucoma
Others

Optical Disorders Drugs Market, By End User:

Diagnostic Centers
Eye Clinics
Hospitals

Optical Disorders Drugs Market, By region:

North America
- United States
- Canada
- Mexico
Asia-Pacific
- China
- India
- South Korea
- Australia
- Japan
Europe
- Germany
- France
- United Kingdom
- Spain
- Italy
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Optical Disorders Drugs Market.

Available Customizations:

Global Optical Disorders Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Optical Disorders Drugs Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Prescription Type (Over-The-Counter Drugs, Prescription Ophthalmic Drugs)
- 5.2.2. By Therapeutics (Age-Related Macular Degeneration, Conjunctivitis, Diabetic Macular Edema, Diabetic Retinopathy, Dry Eye, Eye Cancer, Glaucoma, others)
- 5.2.3. By End User (Diagnostic Centers, Eye Clinics, Hospitals)
- 5.2.4. By Company (2024)
5.3. Market Map

6. Asia Pacific Optical Disorders Drugs Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Prescription Type
- 6.2.2. By Therapeutics
- 6.2.3. By End User
- 6.2.4. By Country
6.3. Asia Pacific: Country Analysis
- 6.3.1. China Optical Disorders Drugs Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Prescription Type
    - 6.3.1.2.2. By Therapeutics
    - 6.3.1.2.3. By End User
- 6.3.2. India Optical Disorders Drugs Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Prescription Type
    - 6.3.2.2.2. By Therapeutics
    - 6.3.2.2.3. By End User
- 6.3.3. Australia Optical Disorders Drugs Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Prescription Type
    - 6.3.3.2.2. By Therapeutics
    - 6.3.3.2.3. By End User
- 6.3.4. Japan Optical Disorders Drugs Market Outlook
  - 6.3.4.1. Market Size & Forecast
    - 6.3.4.1.1. By Value
  - 6.3.4.2. Market Share & Forecast
    - 6.3.4.2.1. By Prescription Type
    - 6.3.4.2.2. By Therapeutics
    - 6.3.4.2.3. By End User
- 6.3.5. South Korea Optical Disorders Drugs Market Outlook
  - 6.3.5.1. Market Size & Forecast
    - 6.3.5.1.1. By Value
  - 6.3.5.2. Market Share & Forecast
    - 6.3.5.2.1. By Prescription Type
    - 6.3.5.2.2. By Therapeutics
    - 6.3.5.2.3. By End User

7. Europe Optical Disorders Drugs Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Prescription Type
- 7.2.2. By Therapeutics
- 7.2.3. By End User
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. France Optical Disorders Drugs Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Prescription Type
    - 7.3.1.2.2. By Therapeutics
    - 7.3.1.2.3. By End User
- 7.3.2. Germany Optical Disorders Drugs Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Prescription Type
    - 7.3.2.2.2. By Therapeutics
    - 7.3.2.2.3. By End User
- 7.3.3. Spain Optical Disorders Drugs Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Prescription Type
    - 7.3.3.2.2. By Therapeutics
    - 7.3.3.2.3. By End User
- 7.3.4. Italy Optical Disorders Drugs Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Prescription Type
    - 7.3.4.2.2. By Therapeutics
    - 7.3.4.2.3. By End User
- 7.3.5. United Kingdom Optical Disorders Drugs Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Prescription Type
    - 7.3.5.2.2. By Therapeutics
    - 7.3.5.2.3. By End User

8. North America Optical Disorders Drugs Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Prescription Type
- 8.2.2. By Therapeutics
- 8.2.3. By End User
- 8.2.4. By Country
8.3. North America: Country Analysis
- 8.3.1. United States Optical Disorders Drugs Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Prescription Type
    - 8.3.1.2.2. By Therapeutics
    - 8.3.1.2.3. By End User
- 8.3.2. Mexico Optical Disorders Drugs Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Prescription Type
    - 8.3.2.2.2. By Therapeutics
    - 8.3.2.2.3. By End User
- 8.3.3. Canada Optical Disorders Drugs Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Prescription Type
    - 8.3.3.2.2. By Therapeutics
    - 8.3.3.2.3. By End User

9. South America Optical Disorders Drugs Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Prescription Type
- 9.2.2. By Therapeutics
- 9.2.3. By End User
- 9.2.4. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Optical Disorders Drugs Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Prescription Type
    - 9.3.1.2.2. By Therapeutics
    - 9.3.1.2.3. By End User
- 9.3.2. Argentina Optical Disorders Drugs Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Prescription Type
    - 9.3.2.2.2. By Therapeutics
    - 9.3.2.2.3. By End User
- 9.3.3. Colombia Optical Disorders Drugs Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Prescription Type
    - 9.3.3.2.2. By Therapeutics
    - 9.3.3.2.3. By End User

10. Middle East and Africa Optical Disorders Drugs Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Prescription Type
- 10.2.2. By Therapeutics
- 10.2.3. By End User
- 10.2.4. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Optical Disorders Drugs Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Prescription Type
    - 10.3.1.2.2. By Therapeutics
    - 10.3.1.2.3. By End User
- 10.3.2. Saudi Arabia Optical Disorders Drugs Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Prescription Type
    - 10.3.2.2.2. By Therapeutics
    - 10.3.2.2.3. By End User
- 10.3.3. UAE Optical Disorders Drugs Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Prescription Type
    - 10.3.3.2.2. By Therapeutics
    - 10.3.3.2.3. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. Global Optical Disorders Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

16.1. Alcon Inc.
- 16.1.1. Business Overview
- 16.1.2. Company Snapshot
- 16.1.3. Products & Services
- 16.1.4. Financials (As Reported)
- 16.1.5. Recent Developments
- 16.1.6. Key Personnel Details
- 16.1.7. SWOT Analysis
16.2. Novartis ag
16.3. Johnson & Johnson services, Inc.
16.4. Bausch health
16.5. Merck & co. Inc.
16.6. Coherus biosciences, Inc.
16.7. Allergan
16.8. Pfizer, Inc.
16.9. Bayer ag
16.10. Santen pharmaceuticals co. Ltd.
16.11. Genetech, Inc.